quinacrine has been researched along with Dermatomyositis in 6 studies
Quinacrine: An acridine derivative formerly widely used as an antimalarial but superseded by chloroquine in recent years. It has also been used as an anthelmintic and in the treatment of giardiasis and malignant effusions. It is used in cell biological experiments as an inhibitor of phospholipase A2.
quinacrine : A member of the class of acridines that is acridine substituted by a chloro group at position 6, a methoxy group at position 2 and a [5-(diethylamino)pentan-2-yl]nitrilo group at position 9.
Dermatomyositis: A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
Excerpt | Relevance | Reference |
---|---|---|
"Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy." | 7.71 | Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. ( Cohen, JB, 2002) |
"We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 7.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
"Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE)." | 5.46 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. ( Alves, P; Bashir, MM; Feng, R; Werth, VP; Wysocka, M; Zeidi, M, 2017) |
"Two patients with cutaneous dermatomyositis unresponsive to combination therapy with prednisone, hydroxychloroquine, quinacrine, and immunosuppressive medications had Dapsone added to their therapy." | 3.71 | Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. ( Cohen, JB, 2002) |
"We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 3.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
"Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE)." | 1.46 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. ( Alves, P; Bashir, MM; Feng, R; Werth, VP; Wysocka, M; Zeidi, M, 2017) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (16.67) | 18.2507 |
2000's | 1 (16.67) | 29.6817 |
2010's | 3 (50.00) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Ravishankar, A | 1 |
Yan, D | 1 |
Bax, CE | 1 |
Concha, JS | 1 |
Feng, R | 2 |
Werth, VP | 4 |
Mittal, L | 1 |
Alves, P | 1 |
Bashir, MM | 1 |
Wysocka, M | 1 |
Zeidi, M | 2 |
Chansky, PB | 1 |
Mehregan, DR | 1 |
Su, WP | 1 |
Cohen, JB | 1 |
6 other studies available for quinacrine and Dermatomyositis
Article | Year |
---|---|
Response of dermatomyositis to the antimalarial quinacrine: A retrospective cohort study.
Topics: Antimalarials; Dermatomyositis; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Middle | 2021 |
The quinacrine experience in a population of patients with cutaneous lupus erythematosus and dermatomyositis.
Topics: Academic Medical Centers; Administration, Oral; Adult; Aged; Antimalarials; Databases, Factual; Derm | 2017 |
Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.
Topics: Antimalarials; Cells, Cultured; Dendritic Cells; Dermatomyositis; Drug Interactions; Humans; Hydroxy | 2017 |
Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings.
Topics: Acute Disease; Autoantibodies; Autoimmune Diseases; Dermatomyositis; Dietary Supplements; Humans; Hy | 2019 |
Cyclosporine treatment for dermatomyositis/polymyositis.
Topics: Azathioprine; Cyclosporine; Dermatomyositis; Female; Humans; Hydroxychloroquine; Middle Aged; Polymy | 1993 |
Cutaneous involvement of dermatomyositis can respond to Dapsone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Dapsone; Dermatomyositis; Diagnosis, Differen | 2002 |